Natera (NASDAQ:NTRA) Shares Down 8.7% – Here’s What Happened

27 Feb 2026, 18:18 by Michael Walen · The Markets Daily

Natera, Inc. (NASDAQ:NTRA – Get Free Report) shares dropped 8.7% on Friday . The company traded as low as $196.22 and last traded at $197.1930. Approximately 610,194 shares were traded during mid-day trading, a decline of 45% from the average daily volume of 1,107,863 shares. The stock had previously closed at $216.10.

Natera News Summary

Here are the key news stories impacting Natera this week:

Positive Sentiment: Natera beat Q4 estimates — reported $0.35 EPS vs. consensus loss and $665.5M revenue (up ~40% year/year), with slide deck and press release detailing results. This quarter’s upside is the primary near-term fundamental catalyst. Natera Reports Q4 and Full‑Year 2025 Financial Results
Positive Sentiment: New clinical data: Natera will present Signatera MRD results at ASCO GU showing utility across genitourinary cancers (including bladder preservation), which supports commercial/clinical adoption of its oncology assays. Signatera MRD Data at ASCO GU
Positive Sentiment: Natera announced results from the SINERGY trial (detail release), which may further validate clinical use cases and support long‑term revenue growth if outcomes are favorable. SINERGY Trial Results
Positive Sentiment: Analyst upgrade/target lift — Robert W. Baird raised its price target to $257 and maintained an Outperform rating, signaling analyst confidence in upside vs. current levels. Baird Raises Price Target
Neutral Sentiment: Street reception: the consensus analyst view is roughly a “Moderate Buy” — shows general positive tilt but not unanimous conviction. Analyst Average Rating
Neutral Sentiment: Full Q4 earnings call and transcript available for details (management commentary on growth drivers, margin progress, and FY26 outlook). Investors will parse the call for guidance clarity. Q4 Press Release / Slide Deck
Negative Sentiment: Profitability uncertainty remains — company metrics still show negative net margin/ROE and analysts expect NTRA to post a negative full‑year EPS; that keeps valuation under pressure despite quarterly beats. Earnings Details & Metrics
Negative Sentiment: Short‑term selling pressure / profit‑taking: despite positive news, the stock is trading lower as investors lock in gains and reassess forward profitability and valuation — this is the most immediate driver of today’s price weakness. Earnings Reaction Coverage

Analysts Set New Price Targets

A number of analysts have commented on the company. Wells Fargo & Company boosted their price objective on Natera from $205.00 to $215.00 and gave the stock an “equal weight” rating in a report on Friday. Robert W. Baird upped their price target on Natera from $239.00 to $257.00 and gave the stock an “outperform” rating in a report on Friday. BTIG Research raised their price objective on Natera from $230.00 to $260.00 and gave the company a “buy” rating in a research note on Friday, December 5th. Morgan Stanley upped their target price on shares of Natera from $220.00 to $265.00 and gave the stock an “overweight” rating in a research note on Monday, December 1st. Finally, Guggenheim raised their price target on shares of Natera from $230.00 to $270.00 and gave the company a “buy” rating in a research report on Monday, January 5th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Natera has an average rating of “Moderate Buy” and an average target price of $254.47.

Read Our Latest Stock Analysis on Natera

Natera Stock Down 6.8%

The firm has a market cap of $27.85 billion, a P/E ratio of -87.93 and a beta of 1.64. The firm’s 50-day simple moving average is $227.00 and its 200 day simple moving average is $203.19.

Natera (NASDAQ:NTRA – Get Free Report) last released its earnings results on Thursday, February 26th. The medical research company reported $0.35 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.81. The firm had revenue of $665.50 million during the quarter, compared to the consensus estimate of $600.68 million. Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. During the same period in the prior year, the firm earned ($0.41) EPS. As a group, analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current year.

Insider Transactions at Natera

In other Natera news, insider Solomon Moshkevich sold 1,639 shares of the business’s stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $230.77, for a total value of $378,232.03. Following the sale, the insider directly owned 137,847 shares in the company, valued at $31,810,952.19. The trade was a 1.18% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Steven Leonard Chapman sold 4,725 shares of the company’s stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $230.77, for a total value of $1,090,388.25. Following the transaction, the chief executive officer directly owned 123,156 shares in the company, valued at $28,420,710.12. This represents a 3.69% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 368,119 shares of company stock valued at $85,956,782. Corporate insiders own 5.63% of the company’s stock.

Hedge Funds Weigh In On Natera

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Palladiem LLC purchased a new stake in shares of Natera during the 4th quarter valued at approximately $31,000. Horizon Investments LLC bought a new stake in Natera during the 3rd quarter valued at $32,000. Bank of Jackson Hole Trust lifted its position in shares of Natera by 103.8% during the fourth quarter. Bank of Jackson Hole Trust now owns 163 shares of the medical research company’s stock worth $37,000 after acquiring an additional 83 shares in the last quarter. Sound Income Strategies LLC boosted its holdings in shares of Natera by 95.7% in the third quarter. Sound Income Strategies LLC now owns 225 shares of the medical research company’s stock worth $39,000 after acquiring an additional 110 shares during the period. Finally, Kemnay Advisory Services Inc. purchased a new position in shares of Natera in the fourth quarter valued at $39,000. Institutional investors own 99.90% of the company’s stock.

Natera Company Profile

(Get Free Report)

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.